Skip to main content

Search GO

VGM & ASSOCIATESHealthcare MSO LEARN ABOUT VGM

Member Q&A From The van Halem Group: New Order Requirement and "Master List"

Published in Billing, Reimbursement, Audits and Compliance on March 02, 2020

Q: "I’m curious about this new order requirement. I see that Medicare updated the notice on 2/12/20, and I’m curious about the “Master List” of items that still need a WOPD. I’m wondering if PAP equipment and supplies fall under the SWO or the WOPD. Can you help me understand?"

A: It is our understanding that everything will be replaced with the SWO, and as of this date, the only items that require the SWO prior to delivery are Power Mobility Devices. PAP equipment (E0601) used to be part of ACA. However, this is no longer the case until the “required list” is published by CMS. We do not have the “required list” as of yet, but I would imagine things that currently require WOPD will continue to require them.

We are told CMS will be providing more guidance in the coming weeks and months and all the articles and policies will need to be updated as it’s a big change. VGM, AAHomecare, and others have posed a number of questions to the contractors and are awaiting a response.

For more information and to stay up to date with regulation changes and clarifications, visit https://blog.vanhalemgroup.com/.

From Our Experts

Reducing Medicare Payments for Urinary Catheters thumbnail

Reducing Medicare Payments for Urinary Catheters The Office of Evaluation and Inspection, a component of OIG (Office of Inspector General) and HHS (Health and Human Services), recently released "Reducing Medicare's Payment Rates for Intermittent Urinary Catheters Can Save the Program and Beneficiaries Millions of Dollars Each Year,” a study that was performed on urinary catheters.

An Open Discussion About Opportunities in the Diabetic Market, CGM Audits, and Reimbursements thumbnail

An Open Discussion About Opportunities in the Diabetic Market, CGM Audits, and Reimbursements In this episode of Industry Matters, we talk with president of The van Halem Group, Wayne van Halem, and sales manager for GEMCO, Joseph Ault, about CGM audits, qualifications for reimbursement and documentation, as well as the opportunities in the diabetic market.

Featured Service: The van Halem Group thumbnail

Featured Service: The van Halem Group There's been a lot of questions and confusion surrounding telehealth services and how they relate to DMEPOS claims. This article by Wayne van Halem, originally featured in “VGM Playbook: Technology and the Patient Care Continuum Guide to Remote Work,” addresses whether or not telehealth services can be used to qualify a patient for an item of DMEPOS during the PHE.

Return of the Audits thumbnail

Return of the Audits HME Business recently wrote about the news that CMS planned to resume audits by Aug. 3 and that it took many by surprise. Then CMS said it would resume audits in a phased approach. What are the details and what can providers expect?

CMS Audits Resume August 3, 2020 thumbnail

CMS Audits Resume August 3, 2020 In this episode, we chat with Wayne van Halem and Kelly Grahovac of The van Halem Group about the CMS audits returning today, August 3, and what DMEPOS providers need to know.

The Cost of Compliance – An Impassioned Plea to be Proactive Last year, The van Halem Group was engaged by several DME providers that were subject to a 6-year OIG lookback audit. Sadly, for companies that did not have a process in place for proactive chart audits, the 6-year look back resulted in a very expensive lesson. Lookback audits are here to stay, and it's never been more important for providers to have a comprehensive proactive compliance program, and this is one way that The van Halem Group can assist members.

OIG to Review PMD Repairs and PAP Supplies thumbnail

OIG to Review PMD Repairs and PAP Supplies The Office of Inspector General (OIG) has updated its work plan to include new reviews for PAP replacement supplies and power mobility device repairs. In a recent article from HME News, Medicare paid approximately $945.8 million for replacement supplies in 2017 and 2018, but OIG has previously found that most claims did not comply with Medicare requirements and that DME suppliers often did not have the documentation required to support the need for replacement supplies.

Are Inhalation Drugs the Next OIG Six Year Lookback Audit? thumbnail

Are Inhalation Drugs the Next OIG Six Year Lookback Audit? Since 2010, the CMS's Comprehensive Error Rate Testing (CERT) program has identified nebulizers and related drugs (i.e., inhalation drugs) among the top 20 supplies with the highest improper Medicare payments. Based on prior reviews, the Office of Inspector General (OIG) conducted a nationwide review to determine if the suppliers included in the review complied with Medicare requirements when billing for inhalation drugs.

Give your business an advantage over the competition.

Become a Member